ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

COLY Coley Pharmaceutical Grp. (MM)

0.00
0.00 (0.00%)
After Hours
Last Updated: -
Delayed by 15 minutes
Share Name Share Symbol Market Type
Coley Pharmaceutical Grp. (MM) NASDAQ:COLY NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0 -

Coley Pharmaceutical Group to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference

26/11/2007 6:29pm

PR Newswire (US)


Coley Pharmaceutical Grp. (MM) (NASDAQ:COLY)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Coley Pharmaceutical Grp. (MM) Charts.
WELLESLEY, Mass., Nov. 26 /PRNewswire-FirstCall/ -- Coley Pharmaceutical Group, Inc. (NASDAQ:COLY), today announced that Robert L. Bratzler, Ph.D., President & Chief Executive Officer, will be presenting a corporate update at the upcoming Lazard Capital Markets Fourth Annual Healthcare Conference at 10:00am ET on November 27th, 2007 at the New York Palace Hotel. Interested parties may access an audio webcast of the presentation by visiting the Coley Pharmaceutical Group website at http://www.coleypharma.com/. A replay of the webcast will be archived on the "Investor Events" page in the Investor Center section of the Coley website for two weeks until December 11th, 2007. About Coley Pharmaceutical Group Coley Pharmaceutical Group, Inc. is an international biopharmaceutical company, headquartered in Wellesley, Massachusetts, USA, that discovers and develops TLR Therapeutics(TM), a new class of investigational drug candidates that direct the human immune system to fight cancers, autoimmune diseases, allergy and asthma disorders and to enhance the effectiveness of vaccines. Coley has established a pipeline of TLR Therapeutic product candidates currently advancing through clinical development with partners and has additional product candidates in preclinical development. Coley has product development, research and license agreements with Pfizer, sanofi-aventis, GlaxoSmithKline, Merck, Novartis Vaccines and the United States government. The company recently announced that it has entered into an agreement to be acquired by Pfizer Inc through a cash tender offer at a price of $8.00 per share. For further information on Coley Pharmaceutical Group please visit http://www.coleypharma.com/. DATASOURCE: Coley Pharmaceutical Group CONTACT: Susan Hager, Sr. Director, Investor Relations and Corporate Communications, of Coley Pharmaceutical Group, +1-781-431-9079, ; Karen L. Bergman, +1-605-575-1509, , or Michelle Corral, +1-415-794-8662, , both of BCC Partners, for Coley Pharmaceutical Group Web site: http://www.coleypharma.com/

Copyright

1 Year Coley Pharmaceutical Grp. (MM) Chart

1 Year Coley Pharmaceutical Grp. (MM) Chart

1 Month Coley Pharmaceutical Grp. (MM) Chart

1 Month Coley Pharmaceutical Grp. (MM) Chart